A new analytic tool for assessing the impact of the <scp>US</scp> Food and Drug Administration regulatory actions-Reference-Cited by-同舟云学术

A new analytic tool for assessing the impact of the US Food and Drug Administration regulatory actions

Published:2022-11-15 Issue:3 Volume:32 Page:298-311
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiology and Drug

Author:

Lu Christine Y.¹,Hou Laura¹,Kolonoski Joy¹,Petrone Andrew B.¹,Zhang Fang¹,Corey Catherine²,Huang Ting‐Ying¹,Bradley Marie C.²^ORCID

Affiliation:

1. Department of Population Medicine Harvard Medical School and the Harvard Pilgrim Health Care Institute Boston Massachusetts USA

2. Division of Epidemiology, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research, US Food and Drug Administration Silver Spring Maryland USA

Funder

U.S. Food and Drug Administration

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5552

Reference21 articles.

1. Communicating the Risks of Medicines

2. Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study

3. Asthma Treatments and Mental Health Visits After a Food and Drug Administration Label Change for Leukotriene Inhibitors

4. FDA drug prescribing warnings: is the black box half empty or half full?

5. Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Six Years of the US Food and Drug Administration's Postmarket Active Risk Identification and Analysis System in the Sentinel Initiative: Implications for Real World Evidence Generation;Clinical Pharmacology & Therapeutics;2023-07-18